To the Editor: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant condition that results from mutations in several genes that lead to mucocutaneous telangiectasias and visceral arteriovenous malformations. 1 Cutaneous telangiectasias do not usually occur until after puberty and the lesions increase in size and number with time. The lesions can be socially stigmatizing for patients and can bleed with minor trauma.
In this study, we explored the role of topical timolol for cutaneous telangiectasias in patients with HHT. Timolol is a potent nonselective betaadrenergic blocking agent possessing 5-to 10-fold greater activity than propranolol, which has been successful in safely treating infantile hemangioma. 2 Timolol can be used topically and has been used by otolaryngologists to treat epistaxis in patients with HHT based on a limited number of cases reported in the literature.
3,4 Proposed mechanisms include vasoconstriction, endothelial cell apoptosis, and decreased vascular endothelial growth factor expression. Based on the reported success, we designed a pilot study to test whether a regular application of topical timolol would reduce the size of and possibly abolish cutaneous telangiectasias in patients with HHT. To our knowledge, there has not been a study evaluating the effect of timolol on cutaneous telangiectasias. In this prospective study, 6 patients with a clinical diagnosis of HHT were enrolled and randomized to apply timolol ophthalmic solution (Timoptic-XE 0.5%; Merck and Co, Whitehouse Station, NJ) topically twice daily to the selected sites of cutaneous telangiectasias on either the left or right side of the body. As a control, patients applied petroleum jelly to the selected lesions on the opposite side of the body. This study was approved by the Institutional Review Board of the Johns Hopkins School of Medicine. Patients were followed 1, 3, and 6 months after the initiation of the treatment. Photographs were taken at each visit and clinical assessments were performed. With the exception of 1 patient who was lost to follow-up, all 5 patients completed the study without any side effects from the treatment.
No significant changes were noted at the end of the study for all skin lesions, which were located on various parts of the body, including the cheeks, nose, arms, and hands (Figs 1 and 2). No appreciable size or color change was detected in the existing lesions despite the patients' good compliance with the protocol. We found the negative results from the study interesting and valuable given the reported success of topical timolol in improving epistaxis in patients with HHT. 4, 5 Given that HHT results from genetic mutations leading to arteriovenous malformations, we expected both the nasal and cutaneous lesions to respond similarly to the beta-blocker. While it is possible that the improvement of epistaxis noted in the otolaryngology literature was coincidental given the unpredictable nature of epistaxis in HHT patients or possibly a transient effect from vasoconstriction, another plausible explanation for our findings could be the difference in the absorption of the medication. Absorption through the nasal mucosa is significantly greater than through the cutaneous route and may explain the difference in efficacy. Future investigation with a gel-forming formulation of the medication, which would have a better penetration through the skin, may be helpful. Additional research with a larger number of HHT patients should also be considered. Our study findings can help to direct future studies with topical timolol, whose indication should be further studied for various vascular lesions in dermatology. Generic propranolol hydrochloride oral solution (Roxane Laboratories by West-Ward Pharmaceuticals, Eatontown, NJ) is commercially available in 2 concentrations: 4 mg/mL and 8 mg/mL. It is widely used off-label to treat high-risk IH at 1 to 3 mg/kg/day in 2 to 3 divided doses.
In 2014, a unique oral pediatric formulation was approved by the US Food and Drug Administration (FDA), and established as first-line therapy for highrisk IH.
3 Hemangeol (Pierre Fabre Pharmaceuticals Inc, Parsippany, NJ) is available in a single concentration of 4.28 mg/mL including the molecular weight of propranolol hydrochloride, as required by the FDA. The recommended dose, calculated in mL/kg, as indicated in the prescribing information, is initiated at 0.15 mL/kg twice daily, with weekly escalation to a goal of 0.4 mL/kg twice daily. This is equivalent to a total dose of 3.4 mg/kg/day. Access to propranolol 4.28 mg/mL is via a single specialty pharmacy, purposefully imposed by the pharmaceutical company to verify dose calculations and provide support to caregivers. Before its approval, most pediatric dermatologists prescribed the lower concentration formulation of generic propranolol (4 mg/mL) to treat IH. We and other prescribers discovered dosing errors from pharmacy dispensing of the higher concentration formulation (8 mg/mL), with a potential risk of overdose in this infant population. We conducted an institutional review boardeapproved survey to identify prescriber experience with pharmacy dispensing errors and dose calculation errors associated with the generic formulations and propranolol 4.28 mg/mL. An online questionnaire was e-mailed to 531 physicians (members of Society for Pediatric Dermatology and physicians that treat IH). Fisher exact and Z tests were used to assess statistical associations.
The response rate was 41.4% (220/531). The majority (70.0%) of responders were pediatric dermatologists. Ninety percent reported prescribing generic propranolol and 58.6% had prescribed propranolol 4.28 mg/mL. At least 1 dispensing error associated with generic propranolol was reported by 18% of physicians (Fig 1) . Among prescribers of generic propranolol, 30% experienced $1 dose calculation error, either made personally or by an assistant. Only 11% of clinicians who prescribed propranolol 4.28 mg/mL reported a similar statistically significant error. A subset analysis of pediatric dermatologists yielded comparable results. Among prescribers with experience writing 10 to 100 prescriptions for generic propranolol and propranolol 4.28 mg/mL, 31% reported $1 dose calculation error with generic propranolol, compared to 10% with propranolol 4.28 mg/mL (Fig 2) . A dosing chart accompanies propranolol 4.28 mg/mL using mL/kg doses, which eliminates conversion from milligrams to milliliters, and could potentially explain the lower 
